Biochemical evaluation of patients with active acromegaly and type 2 diabetes mellitus: Efficacy and safety of the galanin test

Neuroendocrinology

Volumn 88, Issue 4, 2008, Pages 299-304

  Mazziotti, G ^a   Bonadonna, S ^a   Doga, M ^a   Patelli, I ^a   Gazzaruso, C ^b   Solerte, S B ^c   De Menis, E ^d   Giustina, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Clinical Institute 'Beato Matteo'   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d Hospital of Montebelluna   (Italy)

Author keywords

Acromegaly, diagnosis; Active acromegaly; Diabetes mellitus; Galanin

Indexed keywords

GALANIN; GLUCOSE; GROWTH HORMONE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ACROMEGALY; ADULT; AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC TESTS, ROUTINE; FEMALE; GALANIN; GROWTH HORMONE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 57149101700     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000144046     Document Type: Article

References (41)

1. Melmed S: Medical progress: Acromegaly. N Engl J Med 2006;355:2558-2573.
2. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S: Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85:526-529.
3. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A: Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153:737-740.
4. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S, The Pituitary Society and the European Neuroendocrine Association: Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 2003;26:1242-1247.
5. Colao A, Ferone D, Marzullo P, Lombardi G: Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25:102-152.
6. Clayton KL, Holly JMP, Carlson LMS, Jones J, Cheetham TD, Taylor AM, Dunger DB: Loss of normal relationship between growth hormone, growth hormone-binding protein and insulin-like growth factor-1 in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol 1994;41:517-524.
7. Giustina A, Bossoni S, Cimino A, Pizzocolo G, Romanelli G, Wehrenberg WB: Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. J Clin Endocrinol Metab 1990;71:1486-1490.
8. Tan K, Baxter RC: Serum insulin-like growth factor-1 levels in adult diabetic patients: the effect of age. J Clin Endocrinol Metab 1986;63:651-655.
9. Lim DJ, Kwon HS, Cho JH, Kim SH, Choi YH, Yoon KH, Cha BY, Lee KW, Son HY, Kang SK: Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia. Endocr J 2007;54:537-541.
10. Elias AN, Pnadian MR, Naqvi F, Sebag J, Charles MA, Gwinup G: Relationship between prorenin, IGF-I, IGF-binding proteins and retinopathy in diabetic patients. Gen Pharmacol 1996;27:329-332.
11. Dills DG, Moss SE, Klein R, Klein BE: Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes 1991;39:1725-1730.
12. Naidich MJ, Russel EJ Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 1999;28:45-79.
13. Helihy OM, Perros P: Elevated serum growth hormone in a patient with type 1 diabetes: a diagnostic dilemma. Diabetes Metab Res Rev 2000;16:211-216.
14. Hofmann EA, Polonsky KS, Weiss RE: Diagnosis of acromegaly in a patient with type 1 diabetes. Endocr Pract 2002;8:113-118.
15. Ottlecz A, Samson W, McCann SM: Galanin: evidence for a hypothalamic site of action to release growth hormone. Peptides 1985;7:51-53.
16. Giustina A, Veldhuis JD: Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-797.
17. Giustina A, Girelli A, Bodini C, Bonfanti C, Doga M, Schettino M, Negro-Vilar A: Comparative effect of porcine and rat galanin on growth hormone secretion in normal adult men. Horm Metab Res 1992;24:90-91.
18. Giustina A, Bussi AR, Conti C, Doga M, Legati F, Macca C, Zuccato F, Wehrenberg WB: Comparative effect of galanin and pyridostigmine on the growth hormone response to growth hormone-releasing hormone in normal aged subjects. Horm Res 1992;37:165-170.
19. Giustina A, Girelli A, Bossoni S, Legati F, Schettino M, Wehrenberg WB: Effect of galanin on growth hormone-releasing hormone-stimulated growth hormone secretion in adult patients with nonendocrine diseases on long-term daily glucocorticoid treatment. Metabolism 1992;41:548-551.
20. Lawrence AM, Goldfine ID, Kirsteins L: Growth hormone dynamics in acromegaly. J Clin Endocrinol Metab 1970;31:239-243.
21. Giustina A, Bodini C, Doga M, Schettino M, Pizzocolo G, Giustina G: Galanin decreases circulating growth hormone levels in acromegaly. J Clin Endocrinol Metab 1992;74:1296-1300.
22. Giustina A, Bresciani E, Bussi AR, Bollati A, Bonfanti C, Bugari G, Chiesa L, Giustina G: Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly. J Clin Endocrinol Metab 1995;80:1333-1340.
23. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2006;29:S4-S42.
24. Giustina A, Licini M, Schettino M, Doga M, Pizzocolo G, Negro-Vilar A: Physiological role of galanin in the regulation of anterior pituitary function in humans. Am J Physiol 1994;266:E57-E61.
25. Hulting AL, Land T, Berthold M, Langel U, Hokfelt T, Bartfai T: Galanin receptors from human pituitary tumors assayed with human galanin as ligand. Brain Res 1993;15:173-176.
26. Giustina A, Bonfanti C, Licini M, De Rango C, Milani G: Inhibitory effect of galanin on growth hormone release from rat pituitary tumor cells (GH1) in culture. Life Sci 1994;55:1845-1851.
27. De Menis E, Gola M, Giustina A: Development of acromegaly in a patient with anorexia nervosa: pathogenetic and diagnostic implications. J Endocrinol Invest 2006;29:821-825.
28. Hanew K, Kokubun M, Sasaki A, Mouri T, Yoshinaga K: The spectrum of pituitary growth hormone responses to pharmacological stimuli in acromegaly. J Clin Endocrinol Metab 1980;51:292-297.
29. Biermasz NR, Smit JW, van Dulken H, Roelfsema F: Postoperative persistent thyrotrophin-releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. Clin Endocrinol 2002;56:313-319.
30. De Marinis L, Mancini A, Bianchi A, Gentilella R, Valle D, Giampietro A, Zuppi P, Anile C, Maira G, Giustina A: Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. Metabolism 2000;51:616-621.
31. Cimino A, Corsini R, Radaeli E, Bollati A, Giustina G: Transient amaurosis in patients with pituitary macroadenoma after intravenous gonadotropin and thyrotropin-releasing hormones. Lancet 1981;2:95.
32. Szabolcs I, Kesmarki N, Bor K, Czirjak S, Dohan O, Slovik F, Goth M, Kovacs L, Ferencz A, Rimanoczy E, Szilagyi G: Apoplexy of a pituitary macroadenoma as a severe complication of preoperative thyrotropin-releasing hormone testing. Exp Clin Endocrinol Diabetes 1997;105:234-236.
33. Dokmetas HS, Selcuklu A, Colak R, Unluhizarci K, Bayram F, Kelestimur F: Pituitary apoplexy probably due to TRH and GnRH stimulation tests in a patient with acromegaly. J Endocrinol Invest 1999;22:698-700.
34. Yoshino A, Katayama Y, Watanabe T, Ogino A, Ohta T, Komine C, Yokoyama T, Fukushima T, Hirota H: Apoplexy accompanying pituitary adenoma as a complication of preoperative anterior pituitary function tests. Acta Neurochir 2007;149:557-565.
35. Legakis I, Mantzouridis T, Mountokalakis T: Positive correlation of galanin with glucose in type 2 diabetes. Diabetes Care 2005;28:759-760.
36. Zorrilla EP, Brennan M, Sabino V, Lu X, Bartfai T: Galanin type-1 receptor knockout mice show altered responses to high-fat diet and glucose challenge. Physiol Behav 2007;91:479-485.
37. Manabe T, Yoshimura T, Kii E, Tanaka Y, Ohshio G, Tobe T, Akaji K, Yajima H: Galanin-induced hyperglycemia: effect on insulin and glucagon. Endocr Res 1986;12:93-98.
38. Manabe T, Okada Y, Sawai H, Funahashi H, Yamamoto M, Hayakawa T, Yoshimura T: Effect of galanin on plasma glucose, insulin and pancreatic glucagon in dogs. J Int Med Res 2003;31:126-132.
39. Ahren B: Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man. Acta Endocrinol 1990;123:591-597.
40. Holst JJ, Bersani M, Hvidberg A, Knigge U, Christiansen E, Madsbad S, Harling H, Kofod H: On the effects of human galanin in man. Diabetologia 1993;36:653-657.
41. Bauer FE, Zintel A, Kenny MJ, Calder D, Ghatei MA, Bloom SR: Inhibitory effect of galanin on postprandial gastrointestinal motility and gut hormone release in humans. Gastroenterology 1989;97:260-264.